03/25/2025, 07:41 PM UTC
辉瑞的股价仿佛回到了2009年Pfizer Is Trading As If It's 2009 Again
1、辉瑞的股价因强大的产品管线、明智的成本管理和从COVID-19收入下降中恢复而准备增长；2、近期在肿瘤学和疫苗领域的收购和产品发布加强了辉瑞的市场地位和未来的收入流；3、尽管存在关税和药物开发延迟等潜在风险，但辉瑞当前的估值具有吸引力，类似于2008-2009年的水平。1. Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue decline; 2. Recent acquisitions and product launches in oncology and vaccines strengthen Pfizer's market position and future revenue streams; 3. Despite potential risks like tariffs and drug development delays, Pfizer's current valuation is attractive, resembling 2008-2009 levels.---
本文由大语言模型（LLM）生 成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。
